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Abstract
Xenotransplantation faces the dilemma of an unlimited
supply of cells, tissues and organs on the one hand and
severe obstacles and limits on the other. One reason for
the limitations is that the source animal of choice, the
pig, and the human recipient separated 90 million years
ago during evolution, a time in which biological charac-
teristics such as anatomy, physiology and immunology
have had much time to drift far apart. The acceptance of
such an evolutionary widely divergent organ, especially
the heart of a pig, could evoke refusal of xenotransplan-
tation in conservative and religious patients. New legal
aspects of allocation of xenografts have therefore to be
reflected upon and appropriate guidelines developed.
Inquiries show, however, that the acceptance of all types
of porcine organs would be high if the quality of life after
receiving such a xenograft is comparable to that after
receiving the same allograft. This individual benefit of a
xenograft could lead to a disregard of the collective risk
in terms of xenozoonoses, often presented as a catas-
trophic scenarium. Therefore, transplantation societies
and ethics committees have published comments and
even guidelines for handling future clinical xenotrans-
plantation. All three monotheistic religions and Hin-
duism support the idea of saving and improving human
life with the help of an animal organ.
Copyright © 2001 S. Karger AG, Basel
The worldwide lack of organs for transplantation
forces scientists to search for new alternatives to solve this
problem in the near future. Xenotransplantation with its
unlimited sources opens new perspectives to improve this
situation in the next decades. Yet, the last 30 years of
investigation have added many new aspects to the initial-
ly purely immunological approach. Fields like anatomy,
physiology and virology have been discovered to be cru-
cial for the long-term survival of a xenograft and the
patient. Ethical, religious, legal and financial problems
have to be discussed in the interest of the public, especial-
ly in our multicultural societies.
Thus, xenotransplantation faces the dilemma of excel-
lent perspectives on the one hand and severe limits on the
other.
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Choice of Source Animals
Selection of a suitable xenograft for clinical xenotrans-
plantation strongly depends on the phylogeneic relation-
ship between the species of the source animal and man.
Experimental settings clearly indicate that survival times
of xenografts are inversely proportional to the evolutiona-
ry time and/or phylogeneic distance [1].
Transplants between individuals of one zoological fami-
ly, i.e. between zoologically closely related animals like
mouse and rat or man and ape reach survival times similar
to those achieved in allogeneic combinations. The rejec-
tion mechanism is dominated by cellular interactions and
can be mitigated by conventional immunosuppression.
The genetic relationship of species is based on the simi-
larity of the structural and organizational development of
the DNA. In reassociation experiments and DNA-DNA
hybridization, it was shown that 98% of human DNA can
be found in the genes of chimpanzees, 92% in baboons
and 85% in cynomolgus monkeys.
The major histocompatibility locus (MHC) of pri-
mates has been highly conserved throughout the verte-
brate evolution. A large part is similar to that of man.
Mixed lymphocyte reactions show responses in man and
chimpanzee comparable to those in allogeneic combina-
tions. Tissue typing of chimpanzee and baboon was tried
successfully with sera used for human typing.
Enzymes analogous for man possess the same substrate
specificity in most old-world monkeys. Hemoglobins re-
main similar if not identical, and most blood group anti-
gens are comparable and can be tested with the human
tools. All primates, in contrast to most other mammals,
induce isoantibodies. Preformed natural antibodies be-
side the (preformed) isoagglutinins are not found between
chimpanzee and man. These data show that primates and
especially chimpanzees would be the ideal source of
organs for man in terms of histocompatibility. This was
proven in one of the first clinical xenotransplantations
reported by Reemtsma et al. [2]. But several mayor obsta-
cles prohibit the use of nonhuman primates as organ
source. Almost all infectious diseases are transferable
from primates to man. All primates are rare and because
they reproduce slowly are endangered species. In addi-
tion, it is morally not acceptable to use animal species fac-
ing extinction only to treat a few lethally ill, maybe old-age
patients. The production of chimpanzees to a number
needed today for transplantation would last approximate-
ly 100 years, that of baboons 70 years. Prospects which
not only limit but exclude this possibility of transplanta-
tion on a large scale [3].
The optimal animal species for clinical xenotransplan-
tation should be of a size similar to that of the recipient
human being and available in reasonable numbers. It
should be easy to handle and cheap in terms of production
and care. These demands can only be fulfilled by domestic
animals, particularly by the domestic pig.
The disadvantage of this species widely divergent from
man, a discordant combination, is that most characteris-
tics compatible in the primate combination are incompa-
tible between pig and man. The DNA association is less
than 70%. The 15 blood groups found in pigs belong to the
salivatory type, like the Rhesus factor, and like major his-
tocompatibility antigens, they are completely different
from the human type. Isoagglutinins do not exist. The
mean titer of preformed natural antibodies against hu-
man epitopes is one of the highest in the class of mam-
mals.
Enzymes and hormones differ in almost all cases in
over 30% of the amino acid sequences. This means that
no interaction with the human receptors, transmitters,
carrier molecules and inhibitors can be expected. In addi-
tion, molecules with an amino acid sequence of less than
80% identity are antigenic and induce antibodies.
For xenotransplantation, these limitations, developed
by evolution during the last 180 million years, have to be
outwitted before clinical application of pig organs can
start [1].
Transgenic Manipulation of Pigs
In order to prolong the survival time of xenografts
from pigs and to inhibit the mechanisms of the xenogene-
ic hyperacute rejection, transgenic technology was intro-
duced [4]. The carefully directed inhibition of the comple-
ment cascade by introducing the human decay accelerat-
ing factor (h-DAF) gene into the porcine genome has
resulted in a significant inhibition of the xenogeneic
hyperacute rejection process. The inhibition of both the
C3 and C5 convertase blocks the second half of the com-
plement cascade, but has no impact on the first part of the
classical pathway [5]. The introduction of multiple com-
plement regulator genes, in form of a minichromosome
with 3 genes (h-DAF, MCP, CD59), did not add much to
the results of h-DAF only [6].
Other transgenic manipulations like inactivation of the
1,3 Gal-transferase gene by homologous recombination
until today showed only a marginal effect. Transgenic
expression of the FAS-ligand or TRAIL was even less suc-
cessful, inducing enhancement of rejection. Transgenic
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modulation of the blood-clotting cascade is in progress
[7].
The question arises, how many human genes have to
be introduced in the pig genome until an optimal compat-
ible porcine ‘strain’ has been created suitable for xeno-
transplantation. The limit of this technique is not in sight,
but the exchange or knockout of all genes characterizing
porcine incompatible characteristics does not seem to be
feasible in the near future. Pigs justifying cloning for clini-
cal purposes do not yet exist.
The most intriguing problem seems to be the unpre-
dictable and irregular side effects of genetic interferences.
Some of the gene constructs induce multiple changes
including lethal ones [8]. The induction of one human
characteristic promoter is not enough if the human inhibi-
tor is lacking. In the case of the human growth hormone,
the unlimited increase in the foreign organ leads to giant
porcine kidneys or hearts, a situation not compatible with
human life [9].
Capacity of Organs
The applicability of different organs and tissues has
not been sufficiently investigated. Surgical procedures
known from allotransplantation have governed the use of
primary vascularized organs. Little is known about xeno-
geneic tissue like bone, skin and cartilage. Corneas, islets,
thyroids and parathyroids have been taken into consider-
ation. Transplantation of bone marrow has even be tried
in a desperate clinical situation [10].
The results depend heavily on antigenicity and species-
specific function of the grafts. From preliminary results, it
can be assumed that simple organs and tissues are better
feasible than organs and tissues composed of many differ-
ent cell types and products. Islets from the pig seem, judg-
ing by the overall physiological aspect, to be the most
compatible porcine graft, with heart, kidney and liver sit-
uated at the far end.
The porcine liver, producing a myriad of incompatible
molecules, will hardly be equal to the tremendous task of
being a substitute for a human organ for any length of
time. Such chaotic disregulations can lead to deadly mis-
functions in an anyhow lethally ill patient.
If the basic disease is the aim of the treatment, one
could imagine that a few isolated pure hepatocytes, for
example, might be able to produce or replace one lacking
compatible molecule. ·1-Antitrypsin is one such molecule
which, if deficient, leads to an end-stage liver disease in
children and could be replaced. The species-specific and
thus incompatible function of a whole liver, however, is
too multifactorial to be tolerated. Bioreactors could be an
alternative to fill the gap of such a disorder. There exists
an enthusiastic approach concerning the healing of dis-
eases by xenografts. But even slight discrepancies of
action might lead to major metabolic problems. This is
known even from several autologous genetic disorders in
which only one molecule, hormone or enzyme did not
function physiologically, leading to severe malfunction.
Complete cure of a complex disease by the use of xeno-
grafts remains to be proven. In other words, there exist
excellent, good, bad and impossible applications of xeno-
grafts.
Preformed Natural Antibodies
Preformed natural antibodies (PNAb) initiate the clas-
sical pathway of the complement cascade by activating
the endothelial cell layer of blood vessels. Recent work has
proven that galactosyl epitopes, particularly the Gal 1,3
Gal, are the main targets of PNAbs on the surface of the
endothelial cells. Yet, less than 10% of the immunoglobu-
lins are directed against these antigens [11]. Many other
types of antispecies antibodies are supposed.
Various types of elimination procedures for these
PNBAbs exist. Plasmapheresis with columns coated with
sheep antihuman IG absorb most efficiently almost all the
Á-globulins, a situation beneficial in experimental ap-
proaches, but not useful in life-long treatment. Within a
short time, the antibodies reappeared, often showing a
rebound effect [12].
Selective absorption of the anti-1,3 Gal antibodies on
specific columns is expensive and did not achieve the suc-
cess expected. Too many additional antibody types and
classes are left over, and are also able to induce the rejec-
tion mechanism [13]. Immunosuppression and genetic
manipulation has had only a marginal impact on these
preformed antibodies [14–16].
The reappearance of secondary specific antibodies,
now mainly of IgG types, is another limitation for long-
term survival of xenogeneic organs. These antibodies act
in minute amounts and are highly specific. The present
immunosuppression seems to be inefficient. These sec-
ondary antibodies will not allow a retransplantation of an
organ from the same species.
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Viral Transfer and Infection
All mammals are hosts of various types of germs. Most
of them are species specific and not able to contaminate
individuals of other zoological background.
A limited number of infections can be transferred from
one species to another under normal contact. They are
called zoonoses. If transmitted by a xenograft, the disease
is called xenozoonosis. No such disease has been reported
to date. In vitro, various human primary cells and immor-
talized cell lines have been infected with porcine endogen
retroviruses (PERV) [17]. This liberation of C-type vi-
ruses able to infect immortalized human cells was, how-
ever, regarded as a possible cell culture artifact. Using
these methods, 3 types of PERVs can be distinguished
[18]. This finding has evoked severe concern, and several
scientists, especially virologists, have asked for a morato-
rium on xenotransplantation.
Due to the intensified search for viruses other than
PERV, several new viruses have been detected in pigs and
are under investigation for their contagious potential for
man. Since most of these studies do not reflect a clinical
situation, it remains unclear whether PERVs will be trans-
ferred together with a xenograft [19].
The fear that high immunosuppression together with
transgenic manipulations could increase the possibility of
transfection is not verified. One hundred and sixty pa-
tients who had received vital porcine tissue or organs as
transplants were investigated for PERV contamination or
immunological reaction against the xenogeneic virus. No
signs of PERV infection or antibodies against PERV were
found. This is also true for a number of patients with ter-
minal liver disease who were treated by ex vivo perfusion
of h-DAF transgenic porcine livers as a bridge. After allo-
geneic liver transplantation and normal immunosuppres-
sion, no signs of PERV contamination could be proven
either [20]. It is, however, of ethical importance whether
individual benefit should have the advantage over collec-
tive risk. It has to be emphasized, that without clinical
perspectives in the field of xenotransplantation, the inves-
tigation of porcine viruses and germs would not have
received this amount of interest.
Physiological Function
Physiological characteristics change from species to
species. Common attributes like cell division, membrane
structure and intermediate metabolism indicate the close
relationship between man and the other mammals. Other
basic metabolic characteristics like pH, urine production
and osmolarity, blood pressure, temperature regulation
and oxygen uptake in relation to body size are almost
identical in all mammals [21]. But many other character-
istics are so different between species that cooperation,
interaction, integration and maintenance of organ func-
tion are impossible.
Some beneficial developments have been conserved by
nature over millions of years, like for example calcitonin
and insulin in pig and man; others change within a zoolog-
ical family, like tumor necrosis factor ß in primates.
Some of the molecules have, despite a similar amino
acid sequence, a completely different function in other
species. However, messenger molecules must be compat-
ible with the carrier molecules and the receptors. Fast-
reacting mediators must have similar fast-reacting coun-
terparts. The levels of circulating soluble molecules must
match with the number of receptor structures on the tar-
get cell surface. There exist myriads of variations which
can disturb the humoral concert and therefore nullify the
action of the xenograft.
From this point of view, the physiological discrepan-
cies could, after intensive investigation, represent the
most serious limitation, but no systematic investigation in
this direction exists [22].
Blood Groups
The blood groups of animals are extensively studied in
the domestic races [23]. Usually they are of salivatory type
and resemble the human rhesus system. Isoagglutinins are
common in primates, but rare in other species. Therefore,
no primary reaction occurs after the first allogeneic and
even xenogeneic blood transfusion. Preformed natural
antibodies, however, react in any case when porcine red
blood cells (RBCs) are incubated in human serum. The
·-Gal epitope has been identified as one major antigen
also on RBCs. Removal of anti-·-Gal antibodies alone
from the human serum, however, is insufficient to cir-
cumvent antibody-independent immune responses. In
pigs of different races blood group systems A–N have
been described [23]. Only the porcine blood group A-O
was found to have similarities with the human ABO sys-
tem. Absorptions of anti-·-Gal antibodies prove that anti-
non-·-Gal antibodies bind specifically to antigens on pig
RBCs.
In addition, pigs possess the SLA system on white
blood cells and platelets. The gene frequencies of this sys-
tem are only partly differentiated. They will also inevita-
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bly play a role in xenotransplantation and represent
another obstacle [23].
Respiratory pigments like hemo- and myoglobin differ
significantly between pig and man. The structure is relat-
ed to the binding capacity of oxygen. The changes of the
·- and ß-chain deriving from common ancestors differ in
the degree of mutational steps. Only in closely related spe-
cies is hemoglobin similar if not identical [24].
The idea of heterologous blood transfusion is not yet
seen as a future clinical approach. The use of xenogeneic
hemoglobins as oxygen carriers is, however, under inves-
tigation [25].
Blood Viscosity
There exist little data about blood viscosity in various
animals. Blood viscosity differs significantly, due to the
differences in hematocrit of 42% in man and 30% in the
pig. Viscosity depends on the quality of the various blood
components, including total protein and the number and
size of the blood cells. Viscosity expressed as Pascal/sec-
ond is 5.9 Pa/s in the pig as compared to 4.7 Pa/s in man.
This might be due to the flexibility of RBCs, the tendency
to aggregate and the concentration of fibrinogen. Shear
rate and temperature have an impact on viscosity too.
Immunosuppression, which depresses the production of
all blood components, decreases hematocrit and thus vis-
cosity. Because of the higher viscosity in man, a reduced
hemoperfusion of pig organs has to be expected, which
would be especially critical for coronary blood flow [26].
Blood-Clotting System
Vascularized porcine xenografts overexpressing h-
DAF are still lost within weeks by acute vascular rejec-
tion, vascular-based inflammation, thrombo- and leuko-
penia and disseminated intravascular coagulation. These
complications develop despite apheresis of preformed an-
tibodies and despite inhibition of the complement cas-
cade. In other words, xenogeneic blood clotting occurs
independently from immunological mechanisms.
Quiescent endothelial cells express effective anticoagu-
lant mechanisms that maintain microcirculatory homeo-
stasis and vascular integrity under physiological condi-
tions. Activation of endothelial cells within an ultrashort
time lead to a loss of these molecules on the cell surface,
and in addition start intracellular mechanisms which lead
to the expression of molecules which activate the blood-
clotting cascade [27].
It is not known whether incompatible mechanisms are
inoperative or block the clotting cascade, or enhance only
parts of it, leading in any case to a chaos as soon as
extreme anticoagulation by heparin or hirudin is tapered
off.
Molecular incompatibilities of coagulation factors can
already be detected in monkeys leading to thrombotic
microangiopathy as shown in the few cases of clinical
xenotransplantations [28].
In the porcine system, the tissue factor pathway and,
more importantly, the inhibitors (TFPI), the thrombomo-
dulin and the von Willebrand factor are very different.
Porcine TFPI in contrast to human TFPI is not able to
inhibit human factor X activation. Porcine EC induce
higher TF and ICAM-1 expression on human monocytes
compared to human EC. Human prothrombin and factor
X are activated by human EC. First trials to manipulate
these redundant mechanisms are started in mice. How-
ever, achieving a similar expression in pigs faces many
limitations.
Since porcine thrombomodulin does not bind human
thrombin, human protein C is able to generate thrombin,
which, by itself, is responsible for the cessation of micro-
circulation in xenogeneic primate organs [29]. Together
with the enhanced von Willebrand factor, this incompati-
ble interaction will be a major obstacle and limitation for
long-term xenotransplantation.
Microcirculation
The mechanisms described are initiating reactions
which act on the multiple phenomena made visible by his-
tology or more recently by intravital microscopy. Throm-
bin initiates clotting and aggregation of thrombocytes in
parallel to the expression of selectins, integrins and adhe-
sion molecules. In detail, h-DAF acts on the second half of
the complement cascade, while C1–C4 are not inhibited.
C1q results in the activation of the platelet fibrinogen
receptor GPIIa/IIIb with the expression of P selectin on
thrombocytes. But P selectin also promotes the platelet-
leukocyte interaction and thus the monocyte tissue factor.
This can be demonstrated by the immediate loss of plate-
lets and leukocytes in the perfusing xenogeneic blood even
in transgenic models, after the apheresis of preformed
antibodies, splenectomy or heavy immunosuppression
with cyclophosphamide [30].
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Economics of Xenotransplantation
Financing xenotransplantation is a perspective which
has been realized only recently [31]. If xenotransplanta-
tion becomes a reality, more than ten times the number of
today’s transplantations could be performed. Pharmaceu-
tical companies have invested large amounts of money
hoping for a reward in the not too distant future. Since
xenografts are declared as drugs in some countries, they
can be sold. Estimations about the costs of production of
clinically applicable perfectly ‘clean’ transgenic porcine
grafts indicate that in the beginning xenotransplantation
is more expensive than allotransplantation [32].
Kidney transplantation would save costs in the follow-
ing years as compared to dialysis if the organs work long
and immunosuppression is cheap. However, unlimited
numbers of hearts and livers will save many patients who
cannot necessarily go back to work, and will need finan-
cial support either from the governments or health insur-
ances.
Even if xenotransplantation is used for elective trans-
plantation, the precautions like viral tests, preservation of
tissues, isolation or quarantine of the patient and high
immunosuppression will increase the expenditure over
that of allotransplantation.
Ethics and Xenotransplantation
Ethical problems of xenotransplantation are much
more complex than those of allotransplantation. The use
of animal organs is accepted in all Western countries;
however, the acceptance by the recipient is significantly
more multiform than that of a human graft [33]. The
patient’s autonomy, the conflicts of the relatives and the
dignity of the patient must be taken into consideration by
the surgeon even after the permission of the general and
local ethics committee. We have to take into account the
professional ethics and the medical ethos. There could be
a hasty decision in a desperate situation. The aspects of
international reputation and career might play a role.
We have to respect the global impact, the cultural and
the religious situation of our multicultural countries. A
careless surgeon could initiate political and legal contro-
versies.
In fact, these limitations were realized for the first time
in medical history before the actual operation, the clinical
xenotransplantation, had even started. Many committees
have been called to develop guidelines which prevent pos-
sible turmoils about xenotransplantation [34].
A hasty and inconsiderate moratorium of this new and
promising therapy would, however, be contraproductive,
and would not only stop the scientific interest and enthu-
siasm, but also the financial support of this extremely
fruitful field of research – xenobiology.
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